New York, January 18, 2026, 06:30 EST — Market closed
Pfizer Inc (PFE) shares slipped 0.93% to $25.65 on Friday. Reuters reported that some drugmakers harbor quiet concerns over a White House-backed fast FDA review program, fearing it could increase legal risks if a rushed process overlooks safety problems. Pfizer has reportedly considered joining the initiative, according to Reuters.
U.S. stock markets will be closed Monday in observance of Martin Luther King Jr. Day, shortening the trading week and shifting the next session to Tuesday. This heightens the impact of any policy news released before the opening bell.
Drug approvals drive revenue timing in this sector, with the FDA calendar playing a key role in valuation. Move those approvals faster, and you bring sales forward — though it raises concerns about potential oversights.
Last week wrapped up quietly for the broader market. The S&P 500 slipped 0.06% on Friday, while the Dow lost 0.17%, according to Reuters.
Investors are focused on the weight-loss sector, where Novo Nordisk’s Wegovy pill jumped out of the gate in the U.S., racking up 3,071 retail prescriptions in just its first four days, according to IQVIA data cited by Reuters. The FDA is slated to rule by April on Eli Lilly’s experimental weight-loss pill, Reuters reported.
Pfizer’s venture connections surfaced again Friday as Belgian drugmaker Agomab Therapeutics revealed a bigger net loss in its U.S. IPO filing. Pfizer took part in Agomab’s Series B round and ranks among its key shareholders, Reuters reported.
Options activity showed no signs of panic, with around 123,000 contracts traded. Calls outpaced puts, resulting in a put/call ratio of 0.59, data from TheFly revealed. Implied volatility hovered around 24, signaling an expected daily move of about 39 cents.
Pfizer stuck with its 2026 forecast from December, projecting revenue between $59.5 billion and $62.5 billion, with adjusted earnings per share in the $2.80 to $3.00 range. The company flagged a roughly $1.5 billion drop in COVID-19 product revenue compared to 2025, alongside a $1.5 billion annual hit from products losing exclusivity.
The policy angle cuts both ways. If accelerated reviews face legal challenges or lead to label changes post-launch, that “faster” track quickly becomes a headache. It can also inject volatility into a stock that’s mostly acted like a defensive play.
Pfizer’s upcoming dividend is set at $0.43 per share. The ex-dividend date falls on Jan. 23, and the payout will be made on March 6. Investors buying the stock on or after Jan. 23 won’t receive this dividend.
Pfizer’s next major event is set for Feb. 3, when it will release quarterly results and hold its earnings webcast at 10:00 a.m. ET, per its investor calendar. Investors will be watching closely for updates on the 2026 outlook and more clarity on how the company intends to navigate accelerated FDA approval routes without increasing risk.
